Global Influenza Medication Market

Influenza Medication Comprehensive Study by Type (Zanamivir, Oseltamivir phosphate, Peramivir, Other Influenza Medication), Application (Hospitals, Clinics, Pharmacies, Others), Treatment Type (Medication, Chemoprophylaxis, Others), End User (Adult, Kids) Players and Region - Global Market Outlook to 2030

Influenza Medication Market by XX Submarkets | Forecast Years 2024-2030  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
About Influenza Medication
Influenza medication includes antiviral drugs prescribed for the treatment of influenza. Influenza, also known as flu, is a respiratory disease caused by an influenza virus. The high growth of the global influenza medication market is due to unmet medical needs within the annual influenza epidemics along with strong R&D focus resulting in new and advanced treatments and drugs, and increasing demand due to government stockpiling.

AttributesDetails
Study Period2018-2030
Base Year2023
UnitValue (USD Million)


The global market is highly competitive and consists of a limited number of providers who compete with each other. The intense competition, changing consumer spending patterns, demographic trends, and frequent changes in consumer preferences pose significant opportunities for market growth. Analyst at AMA Research estimates that Europe Players will contribute the maximum growth to Global Influenza Medication market throughout the forecasted period. Established and emerging Players should take a closer view at their existing organizations and reinvent traditional business and operating models to adapt to the future.

Bristol-Myers Squibb (United States), AstraZeneca (United Kingdom), Eli Lilly (United States), Roche Holding AG (Switzerland), GlaxoSmithKline (United Kingdom), Novartis International AG (Switzerland), Pfizer (United States), Sanofi (France), Bayer AG (Germany), Celgene (United States) and Seqirus (United Kingdom) are some of the key players that are part of study coverage.

Segmentation Overview
AMA Research has segmented the market of Global Influenza Medication market by Type (Zanamivir, Oseltamivir phosphate, Peramivir and Other Influenza Medication), Application (Hospitals, Clinics, Pharmacies and Others) and Region.



On the basis of geography, the market of Influenza Medication has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). If we see Market by Treatment Type, the sub-segment i.e. Medication will boost the Influenza Medication market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by End User, the sub-segment i.e. Adult will boost the Influenza Medication market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.

Influencing Trend:
Rising awareness about Treatment and Technological Advancement and Increasing Company Initiatives to Enhance R&D

Market Growth Drivers:
High Prevalence of Infectious Diseases across the World and Increasing Demand for Treatment and Novel Therapies

Challenges:
Patent Expiry from many Companies and Introduction of Generic Drugs

Restraints:
Insufficient Awareness about Influenza Treatment in Developing Countries and Effective Treatment is Either Unavailable or Unaffordable

Opportunities:
Favorable Policies for Treatment and Prevention of Influenza by the Government in Developed Countries

Market Leaders and their expansionary development strategies
In October 2019, shionogi and co Ltd,. announced the approval of xofluza 20mg tablets for the treatment of influenza types A and B in patients over the age of 12.
In January 2019, Seqirus a subsidiary of CSL Limited received the European Commission approval for Flucelvax, a quadrivalent influenza vaccine (QIVc) for the treatment of influenza for a patient of age 9 years or above.


Key Target Audience
Manufacturers and Suppliers of Influenza Medication, Research and Development Companies, Medical Research Laboratories, Academic Medical Centers and Universities and Others

About Approach
To evaluate and validate the market size various sources including primary and secondary analysis is utilized. AMA Research follows regulatory standards such as NAICS/SIC/ICB/TRCB, to have a better understanding of the market. The market study is conducted on basis of more than 200 companies dealing in the market regional as well as global areas with the purpose to understand the companies positioning regarding the market value, volume, and their market share for regional as well as global.

Further to bring relevance specific to any niche market we set and apply a number of criteria like Geographic Footprints, Regional Segments of Revenue, Operational Centres, etc. The next step is to finalize a team (In-House + Data Agencies) who then starts collecting C & D level executives and profiles, Industry experts, Opinion leaders, etc., and work towards appointment generation.

The primary research is performed by taking the interviews of executives of various companies dealing in the market as well as using the survey reports, research institute, and latest research reports. Meanwhile, the analyst team keeps preparing a set of questionnaires, and after getting the appointee list; the target audience is then tapped and segregated with various mediums and channels that are feasible for making connections that including email communication, telephonic, skype, LinkedIn Group & InMail, Community Forums, Community Forums, open Survey, SurveyMonkey, etc.

Report Objectives / Segmentation Covered

By Type
  • Zanamivir
  • Oseltamivir phosphate
  • Peramivir
  • Other Influenza Medication
By Application
  • Hospitals
  • Clinics
  • Pharmacies
  • Others
By Treatment Type
  • Medication
  • Chemoprophylaxis
  • Others

By End User
  • Adult
  • Kids

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. High Prevalence of Infectious Diseases across the World
      • 3.2.2. Increasing Demand for Treatment and Novel Therapies
    • 3.3. Market Challenges
      • 3.3.1. Patent Expiry from many Companies and Introduction of Generic Drugs
    • 3.4. Market Trends
      • 3.4.1. Rising awareness about Treatment and Technological Advancement
      • 3.4.2. Increasing Company Initiatives to Enhance R&D
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Influenza Medication, by Type, Application, Treatment Type, End User and Region (value) (2018-2023)
    • 5.1. Introduction
    • 5.2. Global Influenza Medication (Value)
      • 5.2.1. Global Influenza Medication by: Type (Value)
        • 5.2.1.1. Zanamivir
        • 5.2.1.2. Oseltamivir phosphate
        • 5.2.1.3. Peramivir
        • 5.2.1.4. Other Influenza Medication
      • 5.2.2. Global Influenza Medication by: Application (Value)
        • 5.2.2.1. Hospitals
        • 5.2.2.2. Clinics
        • 5.2.2.3. Pharmacies
        • 5.2.2.4. Others
      • 5.2.3. Global Influenza Medication by: Treatment Type (Value)
        • 5.2.3.1. Medication
        • 5.2.3.2. Chemoprophylaxis
        • 5.2.3.3. Others
      • 5.2.4. Global Influenza Medication by: End User (Value)
        • 5.2.4.1. Adult
        • 5.2.4.2. Kids
      • 5.2.5. Global Influenza Medication Region
        • 5.2.5.1. South America
          • 5.2.5.1.1. Brazil
          • 5.2.5.1.2. Argentina
          • 5.2.5.1.3. Rest of South America
        • 5.2.5.2. Asia Pacific
          • 5.2.5.2.1. China
          • 5.2.5.2.2. Japan
          • 5.2.5.2.3. India
          • 5.2.5.2.4. South Korea
          • 5.2.5.2.5. Taiwan
          • 5.2.5.2.6. Australia
          • 5.2.5.2.7. Rest of Asia-Pacific
        • 5.2.5.3. Europe
          • 5.2.5.3.1. Germany
          • 5.2.5.3.2. France
          • 5.2.5.3.3. Italy
          • 5.2.5.3.4. United Kingdom
          • 5.2.5.3.5. Netherlands
          • 5.2.5.3.6. Rest of Europe
        • 5.2.5.4. MEA
          • 5.2.5.4.1. Middle East
          • 5.2.5.4.2. Africa
        • 5.2.5.5. North America
          • 5.2.5.5.1. United States
          • 5.2.5.5.2. Canada
          • 5.2.5.5.3. Mexico
  • 6. Influenza Medication: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2023)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Bristol-Myers Squibb (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. AstraZeneca (United Kingdom)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Eli Lilly (United States)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Roche Holding AG (Switzerland)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. GlaxoSmithKline (United Kingdom)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Novartis International AG (Switzerland)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Pfizer (United States)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Sanofi (France)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Bayer AG (Germany)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Celgene (United States)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
      • 6.4.11. Seqirus (United Kingdom)
        • 6.4.11.1. Business Overview
        • 6.4.11.2. Products/Services Offerings
        • 6.4.11.3. Financial Analysis
        • 6.4.11.4. SWOT Analysis
  • 7. Global Influenza Medication Sale, by Type, Application, Treatment Type, End User and Region (value) (2025-2030)
    • 7.1. Introduction
    • 7.2. Global Influenza Medication (Value)
      • 7.2.1. Global Influenza Medication by: Type (Value)
        • 7.2.1.1. Zanamivir
        • 7.2.1.2. Oseltamivir phosphate
        • 7.2.1.3. Peramivir
        • 7.2.1.4. Other Influenza Medication
      • 7.2.2. Global Influenza Medication by: Application (Value)
        • 7.2.2.1. Hospitals
        • 7.2.2.2. Clinics
        • 7.2.2.3. Pharmacies
        • 7.2.2.4. Others
      • 7.2.3. Global Influenza Medication by: Treatment Type (Value)
        • 7.2.3.1. Medication
        • 7.2.3.2. Chemoprophylaxis
        • 7.2.3.3. Others
      • 7.2.4. Global Influenza Medication by: End User (Value)
        • 7.2.4.1. Adult
        • 7.2.4.2. Kids
      • 7.2.5. Global Influenza Medication Region
        • 7.2.5.1. South America
          • 7.2.5.1.1. Brazil
          • 7.2.5.1.2. Argentina
          • 7.2.5.1.3. Rest of South America
        • 7.2.5.2. Asia Pacific
          • 7.2.5.2.1. China
          • 7.2.5.2.2. Japan
          • 7.2.5.2.3. India
          • 7.2.5.2.4. South Korea
          • 7.2.5.2.5. Taiwan
          • 7.2.5.2.6. Australia
          • 7.2.5.2.7. Rest of Asia-Pacific
        • 7.2.5.3. Europe
          • 7.2.5.3.1. Germany
          • 7.2.5.3.2. France
          • 7.2.5.3.3. Italy
          • 7.2.5.3.4. United Kingdom
          • 7.2.5.3.5. Netherlands
          • 7.2.5.3.6. Rest of Europe
        • 7.2.5.4. MEA
          • 7.2.5.4.1. Middle East
          • 7.2.5.4.2. Africa
        • 7.2.5.5. North America
          • 7.2.5.5.1. United States
          • 7.2.5.5.2. Canada
          • 7.2.5.5.3. Mexico
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Influenza Medication: by Type(USD Million)
  • Table 2. Influenza Medication Zanamivir , by Region USD Million (2018-2023)
  • Table 3. Influenza Medication Oseltamivir phosphate , by Region USD Million (2018-2023)
  • Table 4. Influenza Medication Peramivir , by Region USD Million (2018-2023)
  • Table 5. Influenza Medication Other Influenza Medication , by Region USD Million (2018-2023)
  • Table 6. Influenza Medication: by Application(USD Million)
  • Table 7. Influenza Medication Hospitals , by Region USD Million (2018-2023)
  • Table 8. Influenza Medication Clinics , by Region USD Million (2018-2023)
  • Table 9. Influenza Medication Pharmacies , by Region USD Million (2018-2023)
  • Table 10. Influenza Medication Others , by Region USD Million (2018-2023)
  • Table 11. Influenza Medication: by Treatment Type(USD Million)
  • Table 12. Influenza Medication Medication , by Region USD Million (2018-2023)
  • Table 13. Influenza Medication Chemoprophylaxis , by Region USD Million (2018-2023)
  • Table 14. Influenza Medication Others , by Region USD Million (2018-2023)
  • Table 15. Influenza Medication: by End User(USD Million)
  • Table 16. Influenza Medication Adult , by Region USD Million (2018-2023)
  • Table 17. Influenza Medication Kids , by Region USD Million (2018-2023)
  • Table 18. South America Influenza Medication, by Country USD Million (2018-2023)
  • Table 19. South America Influenza Medication, by Type USD Million (2018-2023)
  • Table 20. South America Influenza Medication, by Application USD Million (2018-2023)
  • Table 21. South America Influenza Medication, by Treatment Type USD Million (2018-2023)
  • Table 22. South America Influenza Medication, by End User USD Million (2018-2023)
  • Table 23. Brazil Influenza Medication, by Type USD Million (2018-2023)
  • Table 24. Brazil Influenza Medication, by Application USD Million (2018-2023)
  • Table 25. Brazil Influenza Medication, by Treatment Type USD Million (2018-2023)
  • Table 26. Brazil Influenza Medication, by End User USD Million (2018-2023)
  • Table 27. Argentina Influenza Medication, by Type USD Million (2018-2023)
  • Table 28. Argentina Influenza Medication, by Application USD Million (2018-2023)
  • Table 29. Argentina Influenza Medication, by Treatment Type USD Million (2018-2023)
  • Table 30. Argentina Influenza Medication, by End User USD Million (2018-2023)
  • Table 31. Rest of South America Influenza Medication, by Type USD Million (2018-2023)
  • Table 32. Rest of South America Influenza Medication, by Application USD Million (2018-2023)
  • Table 33. Rest of South America Influenza Medication, by Treatment Type USD Million (2018-2023)
  • Table 34. Rest of South America Influenza Medication, by End User USD Million (2018-2023)
  • Table 35. Asia Pacific Influenza Medication, by Country USD Million (2018-2023)
  • Table 36. Asia Pacific Influenza Medication, by Type USD Million (2018-2023)
  • Table 37. Asia Pacific Influenza Medication, by Application USD Million (2018-2023)
  • Table 38. Asia Pacific Influenza Medication, by Treatment Type USD Million (2018-2023)
  • Table 39. Asia Pacific Influenza Medication, by End User USD Million (2018-2023)
  • Table 40. China Influenza Medication, by Type USD Million (2018-2023)
  • Table 41. China Influenza Medication, by Application USD Million (2018-2023)
  • Table 42. China Influenza Medication, by Treatment Type USD Million (2018-2023)
  • Table 43. China Influenza Medication, by End User USD Million (2018-2023)
  • Table 44. Japan Influenza Medication, by Type USD Million (2018-2023)
  • Table 45. Japan Influenza Medication, by Application USD Million (2018-2023)
  • Table 46. Japan Influenza Medication, by Treatment Type USD Million (2018-2023)
  • Table 47. Japan Influenza Medication, by End User USD Million (2018-2023)
  • Table 48. India Influenza Medication, by Type USD Million (2018-2023)
  • Table 49. India Influenza Medication, by Application USD Million (2018-2023)
  • Table 50. India Influenza Medication, by Treatment Type USD Million (2018-2023)
  • Table 51. India Influenza Medication, by End User USD Million (2018-2023)
  • Table 52. South Korea Influenza Medication, by Type USD Million (2018-2023)
  • Table 53. South Korea Influenza Medication, by Application USD Million (2018-2023)
  • Table 54. South Korea Influenza Medication, by Treatment Type USD Million (2018-2023)
  • Table 55. South Korea Influenza Medication, by End User USD Million (2018-2023)
  • Table 56. Taiwan Influenza Medication, by Type USD Million (2018-2023)
  • Table 57. Taiwan Influenza Medication, by Application USD Million (2018-2023)
  • Table 58. Taiwan Influenza Medication, by Treatment Type USD Million (2018-2023)
  • Table 59. Taiwan Influenza Medication, by End User USD Million (2018-2023)
  • Table 60. Australia Influenza Medication, by Type USD Million (2018-2023)
  • Table 61. Australia Influenza Medication, by Application USD Million (2018-2023)
  • Table 62. Australia Influenza Medication, by Treatment Type USD Million (2018-2023)
  • Table 63. Australia Influenza Medication, by End User USD Million (2018-2023)
  • Table 64. Rest of Asia-Pacific Influenza Medication, by Type USD Million (2018-2023)
  • Table 65. Rest of Asia-Pacific Influenza Medication, by Application USD Million (2018-2023)
  • Table 66. Rest of Asia-Pacific Influenza Medication, by Treatment Type USD Million (2018-2023)
  • Table 67. Rest of Asia-Pacific Influenza Medication, by End User USD Million (2018-2023)
  • Table 68. Europe Influenza Medication, by Country USD Million (2018-2023)
  • Table 69. Europe Influenza Medication, by Type USD Million (2018-2023)
  • Table 70. Europe Influenza Medication, by Application USD Million (2018-2023)
  • Table 71. Europe Influenza Medication, by Treatment Type USD Million (2018-2023)
  • Table 72. Europe Influenza Medication, by End User USD Million (2018-2023)
  • Table 73. Germany Influenza Medication, by Type USD Million (2018-2023)
  • Table 74. Germany Influenza Medication, by Application USD Million (2018-2023)
  • Table 75. Germany Influenza Medication, by Treatment Type USD Million (2018-2023)
  • Table 76. Germany Influenza Medication, by End User USD Million (2018-2023)
  • Table 77. France Influenza Medication, by Type USD Million (2018-2023)
  • Table 78. France Influenza Medication, by Application USD Million (2018-2023)
  • Table 79. France Influenza Medication, by Treatment Type USD Million (2018-2023)
  • Table 80. France Influenza Medication, by End User USD Million (2018-2023)
  • Table 81. Italy Influenza Medication, by Type USD Million (2018-2023)
  • Table 82. Italy Influenza Medication, by Application USD Million (2018-2023)
  • Table 83. Italy Influenza Medication, by Treatment Type USD Million (2018-2023)
  • Table 84. Italy Influenza Medication, by End User USD Million (2018-2023)
  • Table 85. United Kingdom Influenza Medication, by Type USD Million (2018-2023)
  • Table 86. United Kingdom Influenza Medication, by Application USD Million (2018-2023)
  • Table 87. United Kingdom Influenza Medication, by Treatment Type USD Million (2018-2023)
  • Table 88. United Kingdom Influenza Medication, by End User USD Million (2018-2023)
  • Table 89. Netherlands Influenza Medication, by Type USD Million (2018-2023)
  • Table 90. Netherlands Influenza Medication, by Application USD Million (2018-2023)
  • Table 91. Netherlands Influenza Medication, by Treatment Type USD Million (2018-2023)
  • Table 92. Netherlands Influenza Medication, by End User USD Million (2018-2023)
  • Table 93. Rest of Europe Influenza Medication, by Type USD Million (2018-2023)
  • Table 94. Rest of Europe Influenza Medication, by Application USD Million (2018-2023)
  • Table 95. Rest of Europe Influenza Medication, by Treatment Type USD Million (2018-2023)
  • Table 96. Rest of Europe Influenza Medication, by End User USD Million (2018-2023)
  • Table 97. MEA Influenza Medication, by Country USD Million (2018-2023)
  • Table 98. MEA Influenza Medication, by Type USD Million (2018-2023)
  • Table 99. MEA Influenza Medication, by Application USD Million (2018-2023)
  • Table 100. MEA Influenza Medication, by Treatment Type USD Million (2018-2023)
  • Table 101. MEA Influenza Medication, by End User USD Million (2018-2023)
  • Table 102. Middle East Influenza Medication, by Type USD Million (2018-2023)
  • Table 103. Middle East Influenza Medication, by Application USD Million (2018-2023)
  • Table 104. Middle East Influenza Medication, by Treatment Type USD Million (2018-2023)
  • Table 105. Middle East Influenza Medication, by End User USD Million (2018-2023)
  • Table 106. Africa Influenza Medication, by Type USD Million (2018-2023)
  • Table 107. Africa Influenza Medication, by Application USD Million (2018-2023)
  • Table 108. Africa Influenza Medication, by Treatment Type USD Million (2018-2023)
  • Table 109. Africa Influenza Medication, by End User USD Million (2018-2023)
  • Table 110. North America Influenza Medication, by Country USD Million (2018-2023)
  • Table 111. North America Influenza Medication, by Type USD Million (2018-2023)
  • Table 112. North America Influenza Medication, by Application USD Million (2018-2023)
  • Table 113. North America Influenza Medication, by Treatment Type USD Million (2018-2023)
  • Table 114. North America Influenza Medication, by End User USD Million (2018-2023)
  • Table 115. United States Influenza Medication, by Type USD Million (2018-2023)
  • Table 116. United States Influenza Medication, by Application USD Million (2018-2023)
  • Table 117. United States Influenza Medication, by Treatment Type USD Million (2018-2023)
  • Table 118. United States Influenza Medication, by End User USD Million (2018-2023)
  • Table 119. Canada Influenza Medication, by Type USD Million (2018-2023)
  • Table 120. Canada Influenza Medication, by Application USD Million (2018-2023)
  • Table 121. Canada Influenza Medication, by Treatment Type USD Million (2018-2023)
  • Table 122. Canada Influenza Medication, by End User USD Million (2018-2023)
  • Table 123. Mexico Influenza Medication, by Type USD Million (2018-2023)
  • Table 124. Mexico Influenza Medication, by Application USD Million (2018-2023)
  • Table 125. Mexico Influenza Medication, by Treatment Type USD Million (2018-2023)
  • Table 126. Mexico Influenza Medication, by End User USD Million (2018-2023)
  • Table 127. Company Basic Information, Sales Area and Its Competitors
  • Table 128. Company Basic Information, Sales Area and Its Competitors
  • Table 129. Company Basic Information, Sales Area and Its Competitors
  • Table 130. Company Basic Information, Sales Area and Its Competitors
  • Table 131. Company Basic Information, Sales Area and Its Competitors
  • Table 132. Company Basic Information, Sales Area and Its Competitors
  • Table 133. Company Basic Information, Sales Area and Its Competitors
  • Table 134. Company Basic Information, Sales Area and Its Competitors
  • Table 135. Company Basic Information, Sales Area and Its Competitors
  • Table 136. Company Basic Information, Sales Area and Its Competitors
  • Table 137. Company Basic Information, Sales Area and Its Competitors
  • Table 138. Influenza Medication: by Type(USD Million)
  • Table 139. Influenza Medication Zanamivir , by Region USD Million (2025-2030)
  • Table 140. Influenza Medication Oseltamivir phosphate , by Region USD Million (2025-2030)
  • Table 141. Influenza Medication Peramivir , by Region USD Million (2025-2030)
  • Table 142. Influenza Medication Other Influenza Medication , by Region USD Million (2025-2030)
  • Table 143. Influenza Medication: by Application(USD Million)
  • Table 144. Influenza Medication Hospitals , by Region USD Million (2025-2030)
  • Table 145. Influenza Medication Clinics , by Region USD Million (2025-2030)
  • Table 146. Influenza Medication Pharmacies , by Region USD Million (2025-2030)
  • Table 147. Influenza Medication Others , by Region USD Million (2025-2030)
  • Table 148. Influenza Medication: by Treatment Type(USD Million)
  • Table 149. Influenza Medication Medication , by Region USD Million (2025-2030)
  • Table 150. Influenza Medication Chemoprophylaxis , by Region USD Million (2025-2030)
  • Table 151. Influenza Medication Others , by Region USD Million (2025-2030)
  • Table 152. Influenza Medication: by End User(USD Million)
  • Table 153. Influenza Medication Adult , by Region USD Million (2025-2030)
  • Table 154. Influenza Medication Kids , by Region USD Million (2025-2030)
  • Table 155. South America Influenza Medication, by Country USD Million (2025-2030)
  • Table 156. South America Influenza Medication, by Type USD Million (2025-2030)
  • Table 157. South America Influenza Medication, by Application USD Million (2025-2030)
  • Table 158. South America Influenza Medication, by Treatment Type USD Million (2025-2030)
  • Table 159. South America Influenza Medication, by End User USD Million (2025-2030)
  • Table 160. Brazil Influenza Medication, by Type USD Million (2025-2030)
  • Table 161. Brazil Influenza Medication, by Application USD Million (2025-2030)
  • Table 162. Brazil Influenza Medication, by Treatment Type USD Million (2025-2030)
  • Table 163. Brazil Influenza Medication, by End User USD Million (2025-2030)
  • Table 164. Argentina Influenza Medication, by Type USD Million (2025-2030)
  • Table 165. Argentina Influenza Medication, by Application USD Million (2025-2030)
  • Table 166. Argentina Influenza Medication, by Treatment Type USD Million (2025-2030)
  • Table 167. Argentina Influenza Medication, by End User USD Million (2025-2030)
  • Table 168. Rest of South America Influenza Medication, by Type USD Million (2025-2030)
  • Table 169. Rest of South America Influenza Medication, by Application USD Million (2025-2030)
  • Table 170. Rest of South America Influenza Medication, by Treatment Type USD Million (2025-2030)
  • Table 171. Rest of South America Influenza Medication, by End User USD Million (2025-2030)
  • Table 172. Asia Pacific Influenza Medication, by Country USD Million (2025-2030)
  • Table 173. Asia Pacific Influenza Medication, by Type USD Million (2025-2030)
  • Table 174. Asia Pacific Influenza Medication, by Application USD Million (2025-2030)
  • Table 175. Asia Pacific Influenza Medication, by Treatment Type USD Million (2025-2030)
  • Table 176. Asia Pacific Influenza Medication, by End User USD Million (2025-2030)
  • Table 177. China Influenza Medication, by Type USD Million (2025-2030)
  • Table 178. China Influenza Medication, by Application USD Million (2025-2030)
  • Table 179. China Influenza Medication, by Treatment Type USD Million (2025-2030)
  • Table 180. China Influenza Medication, by End User USD Million (2025-2030)
  • Table 181. Japan Influenza Medication, by Type USD Million (2025-2030)
  • Table 182. Japan Influenza Medication, by Application USD Million (2025-2030)
  • Table 183. Japan Influenza Medication, by Treatment Type USD Million (2025-2030)
  • Table 184. Japan Influenza Medication, by End User USD Million (2025-2030)
  • Table 185. India Influenza Medication, by Type USD Million (2025-2030)
  • Table 186. India Influenza Medication, by Application USD Million (2025-2030)
  • Table 187. India Influenza Medication, by Treatment Type USD Million (2025-2030)
  • Table 188. India Influenza Medication, by End User USD Million (2025-2030)
  • Table 189. South Korea Influenza Medication, by Type USD Million (2025-2030)
  • Table 190. South Korea Influenza Medication, by Application USD Million (2025-2030)
  • Table 191. South Korea Influenza Medication, by Treatment Type USD Million (2025-2030)
  • Table 192. South Korea Influenza Medication, by End User USD Million (2025-2030)
  • Table 193. Taiwan Influenza Medication, by Type USD Million (2025-2030)
  • Table 194. Taiwan Influenza Medication, by Application USD Million (2025-2030)
  • Table 195. Taiwan Influenza Medication, by Treatment Type USD Million (2025-2030)
  • Table 196. Taiwan Influenza Medication, by End User USD Million (2025-2030)
  • Table 197. Australia Influenza Medication, by Type USD Million (2025-2030)
  • Table 198. Australia Influenza Medication, by Application USD Million (2025-2030)
  • Table 199. Australia Influenza Medication, by Treatment Type USD Million (2025-2030)
  • Table 200. Australia Influenza Medication, by End User USD Million (2025-2030)
  • Table 201. Rest of Asia-Pacific Influenza Medication, by Type USD Million (2025-2030)
  • Table 202. Rest of Asia-Pacific Influenza Medication, by Application USD Million (2025-2030)
  • Table 203. Rest of Asia-Pacific Influenza Medication, by Treatment Type USD Million (2025-2030)
  • Table 204. Rest of Asia-Pacific Influenza Medication, by End User USD Million (2025-2030)
  • Table 205. Europe Influenza Medication, by Country USD Million (2025-2030)
  • Table 206. Europe Influenza Medication, by Type USD Million (2025-2030)
  • Table 207. Europe Influenza Medication, by Application USD Million (2025-2030)
  • Table 208. Europe Influenza Medication, by Treatment Type USD Million (2025-2030)
  • Table 209. Europe Influenza Medication, by End User USD Million (2025-2030)
  • Table 210. Germany Influenza Medication, by Type USD Million (2025-2030)
  • Table 211. Germany Influenza Medication, by Application USD Million (2025-2030)
  • Table 212. Germany Influenza Medication, by Treatment Type USD Million (2025-2030)
  • Table 213. Germany Influenza Medication, by End User USD Million (2025-2030)
  • Table 214. France Influenza Medication, by Type USD Million (2025-2030)
  • Table 215. France Influenza Medication, by Application USD Million (2025-2030)
  • Table 216. France Influenza Medication, by Treatment Type USD Million (2025-2030)
  • Table 217. France Influenza Medication, by End User USD Million (2025-2030)
  • Table 218. Italy Influenza Medication, by Type USD Million (2025-2030)
  • Table 219. Italy Influenza Medication, by Application USD Million (2025-2030)
  • Table 220. Italy Influenza Medication, by Treatment Type USD Million (2025-2030)
  • Table 221. Italy Influenza Medication, by End User USD Million (2025-2030)
  • Table 222. United Kingdom Influenza Medication, by Type USD Million (2025-2030)
  • Table 223. United Kingdom Influenza Medication, by Application USD Million (2025-2030)
  • Table 224. United Kingdom Influenza Medication, by Treatment Type USD Million (2025-2030)
  • Table 225. United Kingdom Influenza Medication, by End User USD Million (2025-2030)
  • Table 226. Netherlands Influenza Medication, by Type USD Million (2025-2030)
  • Table 227. Netherlands Influenza Medication, by Application USD Million (2025-2030)
  • Table 228. Netherlands Influenza Medication, by Treatment Type USD Million (2025-2030)
  • Table 229. Netherlands Influenza Medication, by End User USD Million (2025-2030)
  • Table 230. Rest of Europe Influenza Medication, by Type USD Million (2025-2030)
  • Table 231. Rest of Europe Influenza Medication, by Application USD Million (2025-2030)
  • Table 232. Rest of Europe Influenza Medication, by Treatment Type USD Million (2025-2030)
  • Table 233. Rest of Europe Influenza Medication, by End User USD Million (2025-2030)
  • Table 234. MEA Influenza Medication, by Country USD Million (2025-2030)
  • Table 235. MEA Influenza Medication, by Type USD Million (2025-2030)
  • Table 236. MEA Influenza Medication, by Application USD Million (2025-2030)
  • Table 237. MEA Influenza Medication, by Treatment Type USD Million (2025-2030)
  • Table 238. MEA Influenza Medication, by End User USD Million (2025-2030)
  • Table 239. Middle East Influenza Medication, by Type USD Million (2025-2030)
  • Table 240. Middle East Influenza Medication, by Application USD Million (2025-2030)
  • Table 241. Middle East Influenza Medication, by Treatment Type USD Million (2025-2030)
  • Table 242. Middle East Influenza Medication, by End User USD Million (2025-2030)
  • Table 243. Africa Influenza Medication, by Type USD Million (2025-2030)
  • Table 244. Africa Influenza Medication, by Application USD Million (2025-2030)
  • Table 245. Africa Influenza Medication, by Treatment Type USD Million (2025-2030)
  • Table 246. Africa Influenza Medication, by End User USD Million (2025-2030)
  • Table 247. North America Influenza Medication, by Country USD Million (2025-2030)
  • Table 248. North America Influenza Medication, by Type USD Million (2025-2030)
  • Table 249. North America Influenza Medication, by Application USD Million (2025-2030)
  • Table 250. North America Influenza Medication, by Treatment Type USD Million (2025-2030)
  • Table 251. North America Influenza Medication, by End User USD Million (2025-2030)
  • Table 252. United States Influenza Medication, by Type USD Million (2025-2030)
  • Table 253. United States Influenza Medication, by Application USD Million (2025-2030)
  • Table 254. United States Influenza Medication, by Treatment Type USD Million (2025-2030)
  • Table 255. United States Influenza Medication, by End User USD Million (2025-2030)
  • Table 256. Canada Influenza Medication, by Type USD Million (2025-2030)
  • Table 257. Canada Influenza Medication, by Application USD Million (2025-2030)
  • Table 258. Canada Influenza Medication, by Treatment Type USD Million (2025-2030)
  • Table 259. Canada Influenza Medication, by End User USD Million (2025-2030)
  • Table 260. Mexico Influenza Medication, by Type USD Million (2025-2030)
  • Table 261. Mexico Influenza Medication, by Application USD Million (2025-2030)
  • Table 262. Mexico Influenza Medication, by Treatment Type USD Million (2025-2030)
  • Table 263. Mexico Influenza Medication, by End User USD Million (2025-2030)
  • Table 264. Research Programs/Design for This Report
  • Table 265. Key Data Information from Secondary Sources
  • Table 266. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Influenza Medication: by Type USD Million (2018-2023)
  • Figure 5. Global Influenza Medication: by Application USD Million (2018-2023)
  • Figure 6. Global Influenza Medication: by Treatment Type USD Million (2018-2023)
  • Figure 7. Global Influenza Medication: by End User USD Million (2018-2023)
  • Figure 8. South America Influenza Medication Share (%), by Country
  • Figure 9. Asia Pacific Influenza Medication Share (%), by Country
  • Figure 10. Europe Influenza Medication Share (%), by Country
  • Figure 11. MEA Influenza Medication Share (%), by Country
  • Figure 12. North America Influenza Medication Share (%), by Country
  • Figure 13. Global Influenza Medication share by Players 2023 (%)
  • Figure 14. Global Influenza Medication share by Players (Top 3) 2023(%)
  • Figure 15. Global Influenza Medication share by Players (Top 5) 2023(%)
  • Figure 16. BCG Matrix for key Companies
  • Figure 17. Bristol-Myers Squibb (United States) Revenue, Net Income and Gross profit
  • Figure 18. Bristol-Myers Squibb (United States) Revenue: by Geography 2023
  • Figure 19. AstraZeneca (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 20. AstraZeneca (United Kingdom) Revenue: by Geography 2023
  • Figure 21. Eli Lilly (United States) Revenue, Net Income and Gross profit
  • Figure 22. Eli Lilly (United States) Revenue: by Geography 2023
  • Figure 23. Roche Holding AG (Switzerland) Revenue, Net Income and Gross profit
  • Figure 24. Roche Holding AG (Switzerland) Revenue: by Geography 2023
  • Figure 25. GlaxoSmithKline (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 26. GlaxoSmithKline (United Kingdom) Revenue: by Geography 2023
  • Figure 27. Novartis International AG (Switzerland) Revenue, Net Income and Gross profit
  • Figure 28. Novartis International AG (Switzerland) Revenue: by Geography 2023
  • Figure 29. Pfizer (United States) Revenue, Net Income and Gross profit
  • Figure 30. Pfizer (United States) Revenue: by Geography 2023
  • Figure 31. Sanofi (France) Revenue, Net Income and Gross profit
  • Figure 32. Sanofi (France) Revenue: by Geography 2023
  • Figure 33. Bayer AG (Germany) Revenue, Net Income and Gross profit
  • Figure 34. Bayer AG (Germany) Revenue: by Geography 2023
  • Figure 35. Celgene (United States) Revenue, Net Income and Gross profit
  • Figure 36. Celgene (United States) Revenue: by Geography 2023
  • Figure 37. Seqirus (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 38. Seqirus (United Kingdom) Revenue: by Geography 2023
  • Figure 39. Global Influenza Medication: by Type USD Million (2025-2030)
  • Figure 40. Global Influenza Medication: by Application USD Million (2025-2030)
  • Figure 41. Global Influenza Medication: by Treatment Type USD Million (2025-2030)
  • Figure 42. Global Influenza Medication: by End User USD Million (2025-2030)
  • Figure 43. South America Influenza Medication Share (%), by Country
  • Figure 44. Asia Pacific Influenza Medication Share (%), by Country
  • Figure 45. Europe Influenza Medication Share (%), by Country
  • Figure 46. MEA Influenza Medication Share (%), by Country
  • Figure 47. North America Influenza Medication Share (%), by Country
List of companies from research coverage that are profiled in the study
  • Bristol-Myers Squibb (United States)
  • AstraZeneca (United Kingdom)
  • Eli Lilly (United States)
  • Roche Holding AG (Switzerland)
  • GlaxoSmithKline (United Kingdom)
  • Novartis International AG (Switzerland)
  • Pfizer (United States)
  • Sanofi (France)
  • Bayer AG (Germany)
  • Celgene (United States)
  • Seqirus (United Kingdom)
Select User Access Type

Key Highlights of Report


Jan 2024 223 Pages 59 Tables Base Year: 2023 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Influenza Medication Market Quantitative research analysis
Global Influenza Medication Market Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

The standard version of the report profiles players such as Bristol-Myers Squibb (United States), AstraZeneca (United Kingdom), Eli Lilly (United States), Roche Holding AG (Switzerland), GlaxoSmithKline (United Kingdom), Novartis International AG (Switzerland), Pfizer (United States), Sanofi (France), Bayer AG (Germany), Celgene (United States) and Seqirus (United Kingdom) etc.
The Study can be customized subject to feasibility and data availability. Please connect with our sales representative for further information.
"Rising awareness about Treatment and Technological Advancement " is seen as one of major influencing trends for Influenza Medication Market during projected period 2023-2030.
The Influenza Medication market study includes a random mix of players, including both market leaders and some top growing emerging players. Connect with our sales executive to get a complete company list in our research coverage.

Know More About Global Influenza Medication Market Report?

Have a Query? Click Here

Other Related Reports

Raynauds Disease Treatment Comprehensive Study by Type (Primary, Secondary), Application (Hospital, Clinic, Others), Treatment (Medication, - Calcium Channel Blockers, - Vasodilator, Surgeries and Me...
$ 3750
Plasma Therapy Comprehensive Study by Type (Pure PRP, Leucocyte-rich PRP, Pure Platelet-rich Fibrin (PRF), Leukocyte-rich Fibrin (L-PRF)), Application (Orthopedics (Arthritis, Chronic Tendinitis, Bon...
$ 3750
Poultry Bacteriology Diagnostics Comprehensive Study by Type (ELISA Test, PCR Test, Others), Application (Avian Salmonellosis, Avian Influenza, Newcastle Disease, Avian Mycoplasmosis, Avian Pasteurel...
$ 3750
Cold Pain Therapy Comprehensive Study by Type (OTC-Based Products, Prescription-Based Products), Application (Musculoskeletal Disorders, Sport Medicine, Physical Therapy, Post Operative Therapy, Post...
$ 3450
Synovial Sarcoma Treatment Comprehensive Study by Type (High-grade, Low-grade, Translocation-associated), End Users (Hospitals, Specialty Clinics, Oncology Centers, Other), Treatment (Surgery, Anti-A...
$ 3500
Hairy Cell Leukemia Therapeutics Comprehensive Study by Type (Chemotherapy {Cladribine, Pentostatin}, Biologic Therapy {Rituximab, Interferon}, Splenectomy), Application (Hospital, Clinic, Others), D...
$ 3750